N8 Medical

N8 Medical is a clinical-stage medical device company committed to tackling the eradication of Hospital Acquired Infections (HAIs), with a focus on commercializing antimicrobial medical devices and coatings. The company's proprietary approach leverages ceragenins, a novel class of compounds, to transform existing medical devices into high-value assets with antimicrobial, anti-inflammatory, and other therapeutic properties. This not only enhances patient outcomes but also reduces the overall cost of care, addressing the significant multi-billion dollar economic and public health burden associated with HAIs. In April 2017, N8 Medical's CeraShield™ drug-eluting endotracheal tube was designated a "breakthrough device" by the FDA under the 21st Century Cures Act. The company anticipates IDE approval in February 2018, reinforcing its position in the industry.

For more information about N8 Medical, please see www.n8medical.com.